PATENT CLAIM ANALYSIS

Application Number: 15752635
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "265100"]

Abstract:
Janus kinase 1 selective inhibitors and pharmaceutical use thereof are provided.

Claim (Index 12):
The method according to  claim 11 , wherein the autoimmune disease is a skin disease, multiple sclerosis, rheumatoid arthritis, juvenile arthritis, type I diabetes, lupus, psoriasis, inflammatory bowel disease, Crohn's disease, or an autoimmune thyroid disease; the immune system dysfunction is an allograft rejection, a graft-versus-host disease, an allograft rejection reaction, or a graft-versus-host reaction; the viral disease is Epstein-Barr virus (EBV), hepatitis B, hepatitis C, HIV, HTLV 1, chickenpox, herpes zoster virus (VZV), or human papillomavirus (HPV); and the cancer is prostate cancer, lymphoma, leukemia, or multiple myeloma.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 88.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15507409', '14183946', '13928696', '14715046', '13859569']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7859947866969199
- 35 USC 102 Novelty (BERT): 0.554306748473616
- Combined Prediction Score: 0.7628259828745896
- Mean Citation Score: 368.18293400000016
- Max Citation Score: 425.25983
- Similarity Product: 273.7392218154425

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test